معرفی
Michael Paul Murphy, PhD, is a Professor in the Department of Molecular & Cellular Biochemistry at the University of Kentucky, affiliated with the Sanders-Brown Center on Aging. His research focuses on the molecular mechanisms of age-related neurodegenerative diseases, particularly Alzheimer’s disease.
Education:
- B.Sc. in Biochemistry, University of Toronto (1986–1991)
- M.A. in Psychology, University of Toronto (1991–1993)
- Ph.D. in Neuroscience, University of Toronto (1993–1997)
- Post-Doctoral Training, Mayo Clinic, Jacksonville, Florida (1997–2001)
Dr. Murphy's research centers on the amyloid precursor protein (APP) and amyloid-β (Aβ) peptide, key players in Alzheimer’s disease. His work explores how Aβ and APP contribute to neurodegeneration in Alzheimer’s and inclusion body myositis, as well as their intersection with metabolic disorders like type II diabetes. He investigates transcriptional and translational regulation in these pathways and tests therapeutic strategies including NSAIDs, immunotherapy, cholesterol-lowering agents, and dietary changes.
His publications from 2006 to 2024 reflect a consistent focus on Alzheimer’s disease models, amyloid-beta dynamics, astrocyte involvement, sleep disruption effects, and vascular cognitive impairment. These studies employ transgenic mouse models, viral transgenesis, and in vitro systems to understand disease mechanisms and identify therapeutic targets.
Dr. Murphy has not been listed with any scientific awards in the provided text.
He mentors graduate students and leads a research lab investigating neurodegenerative pathways. His work is supported by grants related to aging and neurodegeneration, though specific grant details are not listed. His lab collaborates with the Sanders-Brown Center on Aging to advance translational research.
Dr. Murphy is involved in the Sanders-Brown Center on Aging, where his team studies molecular pathways in age-related diseases using advanced biochemical and neurobiological techniques.
